

# Development of a new class of PSMA target radiopharmaceuticals for prostate cancer

FutureChem Co., Ltd.



ONCOLOGY	Phase 2
Product Type	Radiopharmaceutical, product name: [177Lu]Ludotadipep
Indication	Metastatic Castration Resistant Prostate Cancer (mCRPC)
Target	Prostate Specific Membrane Antigen (PSMA)
MoA(Mechanism of Action)	The beta-ray from Lu-177 of [177Lu]Ludotadipep delivers radiation to PSMA-expressing tumor-cells by binding to cell membrane and internalization, and induces DNA damage which can lead to tumor-cell death
Competitiveness	<ol style="list-style-type: none"> <li>1. Excellent therapeutic effect even with a small dose, ensuring safety through low radiation exposure.</li> <li>2. Albumin binder that structurally allows the compound to bind to albumin protein, which is abundant in the blood.</li> <li>3. Continuous tumor treatment effect even with small dose administration.</li> <li>4. Low radiation exposure and safety through low dose administration.</li> </ol>
Development Stage	Phase 2
Route of Administration	Intravenous injection, repeated